Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R, Armour A, Perez E, Piccart M.

Pharmacogenomics J. 2018 May 22;18(3):480-486. doi: 10.1038/tpj.2017.39. Epub 2017 Aug 8.

PMID:
28786423
2.

No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.

Faulkner L, Meng X, Naisbitt DJ, Spraggs CF, Park BK.

Chem Res Toxicol. 2016 Dec 19;29(12):2111-2113. Epub 2016 Nov 18.

PMID:
27989141
3.

New Approaches to Investigate Drug-Induced Hypersensitivity.

Ogese MO, Ahmed S, Alferivic A, Betts CJ, Dickinson A, Faulkner L, French N, Gibson A, Hirschfield GM, Kammüller M, Meng X, Martin SF, Musette P, Norris A, Pirmohamed M, Park BK, Purcell AW, Spraggs CF, Whritenour J, Naisbitt DJ.

Chem Res Toxicol. 2017 Jan 17;30(1):239-259. doi: 10.1021/acs.chemrestox.6b00333. Epub 2016 Nov 15. Review.

PMID:
27806199
4.

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.

Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN.

Clin Cancer Res. 2016 Mar 15;22(6):1371-7. doi: 10.1158/1078-0432.CCR-15-2044. Epub 2015 Nov 6.

5.

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.

Parham LR, Briley LP, King KS, Byrne J, Rappold E, Goss PE, Spraggs CF.

Pharmacogenomics. 2015;16(11):1227-9. doi: 10.2217/pgs.15.69. Epub 2015 Aug 12.

PMID:
26265235
6.

Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.

Parham LR, Briley LP, Li L, Shen J, Newcombe PJ, King KS, Slater AJ, Dilthey A, Iqbal Z, McVean G, Cox CJ, Nelson MR, Spraggs CF.

Pharmacogenomics J. 2016 Apr;16(2):180-5. doi: 10.1038/tpj.2015.40. Epub 2015 May 19.

7.

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.

Spraggs CF, Parham LR, Song K, Briley LP, Johnson T, Russo M, Tada H, du Bois A, Xu CF.

Ann Oncol. 2015 Jul;26(7):1515-7. doi: 10.1093/annonc/mdv211. Epub 2015 Apr 28. No abstract available.

PMID:
25922065
8.

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.

Xu CF, Johnson T, Garcia-Donas J, Choueiri TK, Sternberg CN, Davis ID, Bing N, Deen KC, Xue Z, McCann L, Esteban E, Whittaker JC, Spraggs CF, Rodríguez-Antona C, Pandite LN, Motzer RJ.

Br J Cancer. 2015 Mar 31;112(7):1190-8. doi: 10.1038/bjc.2015.64.

9.

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.

Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE.

J Clin Oncol. 2014 Aug 1;32(22):2296-303. doi: 10.1200/JCO.2013.52.9867. Epub 2014 Mar 31.

PMID:
24687830
10.

Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.

Spraggs CF, Xu CF, Hunt CM.

Pharmacogenomics. 2013 Apr;14(5):541-54. doi: 10.2217/pgs.13.24. Review.

PMID:
23556451
11.

A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.

Parks D, Lin X, Painter JL, Cheng J, Hunt CM, Spraggs CF, Nelson JJ, Curtis L, Menius JA, Lee KR.

Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):571-8.

PMID:
23300062
12.

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

Xu CF, Xue Z, Bing N, King KS, McCann LA, de Souza PL, Goodman VL, Spraggs CF, Mooser VE, Pandite LN.

Ann Oncol. 2012 Sep;23(9):2470-1. doi: 10.1093/annonc/mds249. No abstract available.

PMID:
22918879
13.

A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.

Newcombe PJ, Reck BH, Sun J, Platek GT, Verzilli C, Kader AK, Kim ST, Hsu FC, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu J.

Genet Epidemiol. 2012 Jan;36(1):71-83. doi: 10.1002/gepi.21600.

14.

Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J.

Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12.

15.

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.

Spraggs CF, Parham LR, Hunt CM, Dollery CT.

Clin Pharmacol Ther. 2012 Apr;91(4):647-52. doi: 10.1038/clpt.2011.277. Epub 2012 Feb 22.

PMID:
22357454
16.

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, de Souza P, Xue ZG, McCann L, King KS, Ragone LJ, Whittaker JC, Spraggs CF, Cardon LR, Mooser VE, Pandite LN.

J Clin Oncol. 2011 Jun 20;29(18):2557-64. doi: 10.1200/JCO.2010.32.9110. Epub 2011 May 16.

PMID:
21576632
17.

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.

Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR.

J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18.

PMID:
21245432
18.

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.

Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, Koshy B, Spraggs CF, Mooser VE, Cardon LR, Pandite LN.

J Hepatol. 2011 Jun;54(6):1237-43. doi: 10.1016/j.jhep.2010.09.028. Epub 2011 Feb 12.

PMID:
21145803
19.

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.

Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, Chen EP, Ellens HE, Mooser VE, Cardon LR, Spraggs CF, Pandite L.

Br J Cancer. 2010 Apr 27;102(9):1371-7. doi: 10.1038/sj.bjc.6605653. Epub 2010 Apr 13.

20.

Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects.

Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, Stubbins M, Roses AD.

Pharmacogenet Genomics. 2005 Dec;15(12):883-9.

PMID:
16272960
21.

Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery.

Diemunsch P, Schoeffler P, Bryssine B, Cheli-Muller LE, Lees J, McQuade BA, Spraggs CF.

Br J Anaesth. 1999 Feb;82(2):274-6.

22.

Role of gastrin/CCK-B receptors in meal-stimulated acid secretion in rats.

Aurang K, Spraggs CF, Jordan C, Lloyd KC.

Am J Physiol. 1997 May;272(5 Pt 1):G1243-8.

PMID:
9176236
23.

The beta 3-adrenoceptor agonist CL316243 prevents indomethacin-induced jejunal ulceration in the rat by reversing early villous shortening.

Anthony A, Bahl AK, Oakley IG, Spraggs CF, Dhillon AP, Trevethick MA, Piasecki C, Pounder RE, Wakefield AJ.

J Pathol. 1996 Jul;179(3):340-6.

PMID:
8774493
24.
25.

Role of pepsin in the development of indomethacin-induced antral ulceration in the rat.

Gaw AJ, Williams LV, Spraggs CF, Jordan CC.

Aliment Pharmacol Ther. 1995 Apr;9(2):167-72.

PMID:
7605857
28.

Transmucosal electrical resistance in rabbit isolated gastric mucosa during exposure to acid.

Spencer GE, Spraggs CF, Stables R, Hirst BH.

J Physiol. 1992 Apr;449:169-81.

31.

Alpha 2-adrenoceptors and the delay of castor oil-induced diarrhoea by clonidine in rats.

Spraggs CF, Bunce KT.

J Pharm Pharmacol. 1983 May;35(5):321-2. No abstract available.

PMID:
6134803
32.

Selective activity of cyclokinins.

Spraggs CF, Margolius HS, Cuthbert AW.

J Pharm Pharmacol. 1983 Apr;35(4):266-8. No abstract available.

PMID:
6133944
33.
34.

Relationship between lesion formation and permeability of rat gastric mucosa to H+ and other cations.

Bunce KT, McCarthy JJ, Spraggs CF, Stables R.

Br J Pharmacol. 1982 Feb;75(2):325-31.

Supplemental Content

Loading ...
Support Center